Once-daily SPIRIVA RESPIMAT 1.25 mcg is the only soft mist LAMA
Make sure patients are familiar with Instructions for Use from the Prescribing Information.
Remind patients not to use more than 2 puffs every 24 hours.1
SPIRIVA RESPIMAT 1.25 mcg has a demonstrated safety profile based on multiple clinical trials with almost 3000 patients with asthma1
Number of asthma patients exposed to SPIRIVA RESPIMAT with adverse reactions >2% (and higher than placebo): pooled data from 4 adult clinical trials with treatment periods ranging between 12 weeks and 52 weeks1:
ADVERSE REACTION* | SPIRIVA RESPIMAT,2.5 mcg (two 1.25-mcg puffs) (n=787) | PLACEBO(n=735) |
|---|---|---|
Pharyngitis | 125 (15.9%) | 91 (12.4%) |
Headache | 30 (3.8%) | 20 (2.7%) |
Bronchitis | 26 (3.3%) | 10 (1.4%) |
Sinusitis | 21 (2.7%) | 10 (1.4%) |
-
*
Adverse reactions include a grouping of similar terms.
Steroid-sparing SPIRIVA RESPIMAT 1.25 mcg did not have any additional side effects for pediatric and adolescent patients
The adverse reaction profiles for pediatric patients (aged 6 to 11 years) and for adolescent patients (aged 12 to 17 years) were comparable to that observed in adult patients.1
Drug interactions with concomitant respiratory medications
SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, chromones, and anti-IgE treatment without increases in adverse reactions.1
Drug interactions with other anticholinergics
There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.1
LAMA, long-acting antimuscarinic agent; IgE, immunoglobulin E.
SPIRIVA RESPIMAT, 1.25 mcg, is a bronchodilator indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. SPIRIVA RESPIMAT is not indicated for relief of acute bronchospasm.
SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product. Immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported.
SPIRIVA RESPIMAT is intended as a once-daily maintenance treatment for asthma and should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. In the event of an attack, a rapid-acting beta2-agonist should be used.
Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue, or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of SPIRIVA RESPIMAT. If such a reaction occurs, discontinue SPIRIVA RESPIMAT at once and consider alternative treatments. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT.
Inhaled medicines, including SPIRIVA RESPIMAT, may cause paradoxical bronchospasm. If this occurs, it should be treated with an inhaled short-acting beta2-agonist, such as albuterol. Treatment with SPIRIVA RESPIMAT should be stopped and other treatments considered.
SPIRIVA RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Since dizziness and blurred vision may occur with the use of SPIRIVA RESPIMAT, caution patients about engaging in activities such as driving a vehicle, or operating appliances or machinery.
SPIRIVA RESPIMAT should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA RESPIMAT should be monitored closely for anticholinergic side effects.
The most common adverse reactions >2% incidence and higher than placebo with SPIRIVA RESPIMAT (placebo) in asthma trials in adults were pharyngitis 15.9% (12.4%), headache 3.8% (2.7%), bronchitis 3.3% (1.4%), and sinusitis 2.7% (1.4%). The adverse reaction profile for adolescent and pediatric patients was comparable to that observed in adult patients with asthma.
SPIRIVA RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs.
Inform patients not to spray SPIRIVA RESPIMAT into the eyes as this may cause blurring of vision and pupil dilation.
Please see full Prescribing Information, including Instructions for Use, for SPIRIVA RESPIMAT.
CL-SVR-0044 2.15.2017
REFERENCE
-
SPIRIVA RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; November 2021.